132 related articles for article (PubMed ID: 25931577)
1. INPP4B, a new player in the chemoresistance of AML.
Recher C
Blood; 2015 Apr; 125(18):2738-9. PubMed ID: 25931577
[No Abstract] [Full Text] [Related]
2. Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML.
Rijal S; Fleming S; Cummings N; Rynkiewicz NK; Ooms LM; Nguyen NY; Teh TC; Avery S; McManus JF; Papenfuss AT; McLean C; Guthridge MA; Mitchell CA; Wei AH
Blood; 2015 Apr; 125(18):2815-24. PubMed ID: 25736313
[TBL] [Abstract][Full Text] [Related]
3. INPP4B-mediated DNA repair pathway confers resistance to chemotherapy in acute myeloid leukemia.
Wang P; Ma D; Wang J; Fang Q; Gao R; Wu W; Cao L; Hu X; Zhao J; Li Y
Tumour Biol; 2016 Sep; 37(9):12513-12523. PubMed ID: 27342972
[TBL] [Abstract][Full Text] [Related]
4. INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia.
Dzneladze I; He R; Woolley JF; Son MH; Sharobim MH; Greenberg SA; Gabra M; Langlois C; Rashid A; Hakem A; Ibrahimova N; Arruda A; Löwenberg B; Valk PJ; Minden MD; Salmena L
Leukemia; 2015 Jul; 29(7):1485-95. PubMed ID: 25736236
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylation of CpG sites at the promoter region is associated with deregulation of mitochondrial ATPsyn-β and chemoresistance in acute myeloid leukemia.
Yang J; Xiao X; Li R; Li Z; Deng M; Zhang G
Cancer Biomark; 2016; 16(1):81-8. PubMed ID: 26835708
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNAs have pivotal roles in chemoresistance of acute myeloid leukemia.
Izadirad M; Jafari L; James AR; Unfried JP; Wu ZX; Chen ZS
Drug Discov Today; 2021 Jul; 26(7):1735-1743. PubMed ID: 33781951
[TBL] [Abstract][Full Text] [Related]
7. IRF2-INPP4B axis participates in the development of acute myeloid leukemia by regulating cell growth and survival.
Zhang F; Zhu J; Li J; Zhu F; Zhang P
Gene; 2017 Sep; 627():9-14. PubMed ID: 28579269
[TBL] [Abstract][Full Text] [Related]
8. Expression of three different ATP-binding cassette transporters and correlation to chemoresistance in acute myeloid leukemia.
Palaiologou D; Panayiotidis P; Papanikolaou G; Georgiou G; Boutsikas G; Hatzinicolaou SL; Pangalis GA; Sakellaropoulos N; Vassilakopoulos TP; Angelopoulou MK
Int J Lab Hematol; 2015 Feb; 37(1):e7-e10. PubMed ID: 24809224
[No Abstract] [Full Text] [Related]
9. Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy.
Bret C; Viziteu E; Kassambara A; Moreaux J
Expert Rev Hematol; 2016; 9(4):351-60. PubMed ID: 26761438
[TBL] [Abstract][Full Text] [Related]
10. IRF2-INPP4B-mediated autophagy suppresses apoptosis in acute myeloid leukemia cells.
Zhang F; Li J; Zhu J; Liu L; Zhu K; Cheng S; Lv R; Zhang P
Biol Res; 2019 Mar; 52(1):11. PubMed ID: 30876449
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs.
Zebisch A; Hatzl S; Pichler M; Wölfler A; Sill H
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27973410
[TBL] [Abstract][Full Text] [Related]
12. Integrating resistance functions to predict response to induction chemotherapy in de novo acute myeloid leukemia.
Chiu YC; Hsiao TH; Tsai JR; Wang LJ; Ho TC; Hsu SL; Teng CJ
Eur J Haematol; 2019 Oct; 103(4):417-425. PubMed ID: 31356696
[TBL] [Abstract][Full Text] [Related]
13. In vitro all-trans retinoic acid sensitivity of acute myeloid leukemia blasts with NUP98/RARG fusion gene.
Such E; Cordón L; Sempere A; Villamón E; Ibañez M; Luna I; Gómez-Seguí I; López-Pavía M; Alonso C; Lo-Coco F; Cervera J; Sanz MA
Ann Hematol; 2014 Nov; 93(11):1931-3. PubMed ID: 24728721
[No Abstract] [Full Text] [Related]
14. Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.
Scholl S; Spies-Weisshart B; Klink A; Muegge LO; Fricke HJ; Hochhaus A
Ann Hematol; 2011 Apr; 90(4):473-5. PubMed ID: 20652568
[No Abstract] [Full Text] [Related]
15. Favorable outcomes of NPM1
Khan I; Kaempf A; Raghuwanshi S; Chesnokov M; Zhang X; Wang Z; Domling A; Tyner JW; Camacho C; Gartel AL
Blood Cancer J; 2023 Aug; 13(1):128. PubMed ID: 37607920
[No Abstract] [Full Text] [Related]
16. LncRNA KCNQ1OT1 contributes to the progression and chemoresistance in acute myeloid leukemia by modulating Tspan3 through suppressing miR-193a-3p.
Sun H; Sun Y; Chen Q; Xu Z
Life Sci; 2020 Jan; 241():117161. PubMed ID: 31837329
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of LncRNA-UCA1 suppresses chemoresistance of pediatric AML by inhibiting glycolysis through the microRNA-125a/hexokinase 2 pathway.
Zhang Y; Liu Y; Xu X
J Cell Biochem; 2018 Jul; 119(7):6296-6308. PubMed ID: 29663500
[TBL] [Abstract][Full Text] [Related]
18. SubID, a non-median dichotomization tool for heterogeneous populations, reveals the pan-cancer significance of INPP4B and its regulation by EVI1 in AML.
Dzneladze I; Woolley JF; Rossell C; Han Y; Rashid A; Jain M; Reimand J; Minden MD; Salmena L
PLoS One; 2018; 13(2):e0191510. PubMed ID: 29415082
[TBL] [Abstract][Full Text] [Related]
19. TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2.
Li Q; Song W; Wang J
Biomed Pharmacother; 2019 Jan; 109():1793-1801. PubMed ID: 30551433
[TBL] [Abstract][Full Text] [Related]
20. FOXM1 contributes to treatment failure in acute myeloid leukemia.
Khan I; Halasi M; Patel A; Schultz R; Kalakota N; Chen YH; Aardsma N; Liu L; Crispino JD; Mahmud N; Frankfurt O; Gartel AL
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
